Recombinant benefits win out

Recombinant benefits win out

BETHESDA, Md. - The safety benefits inherent in a recombinant product persuaded members of the FDA's Blood Products Advisory Committee last week to recommend approval of Genetic Institute Inc.'s BeneFix Coagulation Factor IX to treat hemophilia B despite concerns about the small number of patients involved in GENIZ's trials and indications that BeneFix is less potent than the

Read the full 620 word article

How to gain access

Continue reading with a
two-week free trial.